28-06-2025
Nuvama Keeps Their Buy Rating on Lupin Limited (LUPIN)
In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Buy rating on Lupin Limited (LUPIN – Research Report), with a price target of INR2,530.00. The company's shares closed yesterday at INR1,935.20.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited.
Currently, the analyst consensus on Lupin Limited is a Strong Buy with an average price target of INR2,328.75.
Based on Lupin Limited's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR55.62 billion and a net profit of INR7.73 billion. In comparison, last year the company earned a revenue of INR48.95 billion and had a net profit of INR3.59 billion
